These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

969 related articles for article (PubMed ID: 30559466)

  • 21. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
    Höftberger R; Sepulveda M; Armangue T; Blanco Y; Rostásy K; Calvo AC; Olascoaga J; Ramió-Torrentà L; Reindl M; Benito-León J; Casanova B; Arrambide G; Sabater L; Graus F; Dalmau J; Saiz A
    Mult Scler; 2015 Jun; 21(7):866-874. PubMed ID: 25344373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
    Mariotto S; Gajofatto A; Batzu L; Delogu R; Sechi G; Leoni S; Pirastru MI; Bonetti B; Zanoni M; Alberti D; Schanda K; Monaco S; Reindl M; Ferrari S
    Neurology; 2019 Nov; 93(20):e1867-e1872. PubMed ID: 31645473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
    Tajfirouz DA; Bhatti MT; Chen JJ
    Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM).
    Carnero Contentti E; Lopez PA; Pettinicchi JP; Pappolla A; Miguez J; Patrucco L; Cristiano E; Vrech C; Tkachuk V; Liwacki S; Correale J; Marrodan M; Gaitán MI; Fiol M; Negrotto L; Ysrraelit MC; Burgos M; Leguizamon F; Tavolini D; Deri N; Balbuena ME; Mainella C; Luetic G; Blaya P; Hryb J; Menichini ML; Alvez Pinheiro A; Nofal P; Zanga G; Barboza A; Martos I; Lazaro L; Alonso R; Silva E; Bestoso S; Fracaro ME; Carrá A; Garcea O; Fernandez Liguori N; Alonso Serena M; Caride A; Rojas JI
    Mult Scler Relat Disord; 2021 Apr; 49():102742. PubMed ID: 33454601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.
    Narayan R; Simpson A; Fritsche K; Salama S; Pardo S; Mealy M; Paul F; Levy M
    Mult Scler Relat Disord; 2018 Oct; 25():66-72. PubMed ID: 30048919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spectrum of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases: an Indian perspective.
    Chaudhuri J; Biswas T; Ganguly G; Datta S; Pandit A; Biswas A
    Acta Neurol Belg; 2021 Aug; 121(4):927-931. PubMed ID: 32314270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study.
    Armangue T; Olivé-Cirera G; Martínez-Hernandez E; Sepulveda M; Ruiz-Garcia R; Muñoz-Batista M; Ariño H; González-Álvarez V; Felipe-Rucián A; Jesús Martínez-González M; Cantarín-Extremera V; Concepción Miranda-Herrero M; Monge-Galindo L; Tomás-Vila M; Miravet E; Málaga I; Arrambide G; Auger C; Tintoré M; Montalban X; Vanderver A; Graus F; Saiz A; Dalmau J;
    Lancet Neurol; 2020 Mar; 19(3):234-246. PubMed ID: 32057303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China.
    Wang L; ZhangBao J; Zhou L; Zhang Y; Li H; Li Y; Huang Y; Wang M; Lu C; Lu J; Zhao C; Quan C
    Eur J Neurol; 2019 Jan; 26(1):168-174. PubMed ID: 30133068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel.
    Brill L; Ganelin-Cohen E; Dabby R; Rabinowicz S; Zohar-Dayan E; Rein N; Aloni E; Karmon Y; Vaknin-Dembinsky A
    Front Neurol; 2020; 11():612304. PubMed ID: 33584514
    [No Abstract]   [Full Text] [Related]  

  • 33. Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008‒2018: A nationwide, population-based cohort study.
    Boesen MS; Jensen PEH; Born AP; Magyari M; Nilsson AC; Hoei-Hansen C; Blinkenberg M; Sellebjerg F
    Mult Scler Relat Disord; 2019 Aug; 33():162-167. PubMed ID: 31276927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MOG antibody-related disorders: common features and uncommon presentations.
    Cobo-Calvo Á; Ruiz A; D'Indy H; Poulat AL; Carneiro M; Philippe N; Durand-Dubief F; Deiva K; Vukusic S; Desportes V; Marignier R
    J Neurol; 2017 Sep; 264(9):1945-1955. PubMed ID: 28770374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
    Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
    Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system.
    Tanaka M; Tanaka K
    J Neuroimmunol; 2014 May; 270(1-2):98-9. PubMed ID: 24703097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Optic neuropathy in positive anti-MOG antibody syndrome].
    Merabtene L; Vignal Clermont C; Deschamps R
    J Fr Ophtalmol; 2019 Dec; 42(10):1100-1110. PubMed ID: 31732265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease.
    Rosenthal JF; Hoffman BM; Tyor WR
    J Investig Med; 2020 Feb; 68(2):321-330. PubMed ID: 31582425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].
    Jarius S; Paul F; Aktas O; Asgari N; Dale RC; de Seze J; Franciotta D; Fujihara K; Jacob A; Kim HJ; Kleiter I; Kümpfel T; Levy M; Palace J; Ruprecht K; Saiz A; Trebst C; Weinshenker BG; Wildemann B
    Nervenarzt; 2018 Dec; 89(12):1388-1399. PubMed ID: 30264269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.